BPA call for QTY 16 netspot (gallium-68 dotatate)
Ended Awarded
- Contract number
- N0025922F0127
- Awardee
-
RLS (USA) Inc. UEI UA3GDUKRYSM5
- Awarding agency
-
Bureau of Medicine and Surgery
Department of the Navy, Department of Defense
- Obligated
- $48,000
Award facts
- Contract value 100% obligated
- $48,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Tampa, FL 33614, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency awarded a BPA (Blanket Purchase Agreement) call to RLS (USA) Inc. for the delivery of 16 units of NETSPOT (Gallium-68 Dotatate), a specialized radiopharmaceutical diagnostic imaging agent used in nuclear medicine procedures. The contract, awarded on June 1, 2022, carries a ceiling value of $48,000 and a firm fixed-price structure with an ultimate completion date of June 2, 2022. The place of performance is located in Tampa, Florida. This BPA call represents a task order issued against RLS (USA) Inc.'s existing blanket purchase agreement with the Defense Health Agency for radiopharmaceutical products and services supporting military treatment facilities.
RLS (USA) Inc., a foreign-owned radiopharmacy company headquartered in Lake Mary, Florida, operates 31 radiopharmacy facilities across 18 states and serves as a critical supplier of specialized radiopharmaceutical products to the Department of Veterans Affairs and the Defense Health Agency. The company maintains an extensive portfolio of medical isotopes and diagnostic imaging agents and holds multiple large indefinite delivery contracts with VA Veterans Integrated Service Networks and the Defense Health Agency, establishing RLS (USA) Inc. as a preferred supplier for time-sensitive nuclear medicine products. No set-aside designation was applied to this particular BPA call, allowing full and open competition principles to govern the procurement.
Quick answers
Who was awarded contract N0025922F0127?
N0025922F0127 was awarded to RLS (USA) Inc. by Bureau of Medicine and Surgery (Department of the Navy) on June 1, 2022.
How much is contract N0025922F0127 worth?
The government has obligated $48,000 on N0025922F0127.
Which agency awarded contract N0025922F0127?
Bureau of Medicine and Surgery (Department of the Navy) awarded N0025922F0127, with funding from Defense Health Agency (Department of Defense).
Is contract N0025922F0127 an order under another contract?
Yes. N0025922F0127 is a BPA call under N0025922A0003, a blanket purchase agreement.
Was contract N0025922F0127 competed?
The extent of competition for N0025922F0127 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award